EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment

References

• Adams JB, Holloway CE, George F, Quig D. 2006. Analyses of toxic metals and essential minerals in the hair of Arizona children with autism and associated conditions, and their mothers. Biol Trace Elem Res 110:193–209.
   PubMed Web of Science ®Google Scholar
• al-Refaie FN, Wonke B, Wickens DG, Aydinok Y, Fielding A, Hoffbrand AV. 1994. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. J Clin Pathol 47:657–660.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Hubacek J, Wyse DG, Knudtson ML. 2003. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. J Am Coll Cardiol 41:420–425.
   PubMed Web of Science ®Google Scholar
• Anonymous. Royal Society of Chemistry Data Book. Stability constants for metal ion complexes. Available at: www.chemsoc.org/networks/learnnet/data.htm
   Google Scholar
• Arkadopoulos N, Nastos C, Kalimeris K, Economou E, Theodoraki K, Kouskouni E, Pafiti A, Kostopanagiotou G, Smyrniotis V. 2010. Iron chelation for amelioration of liver ischemia-reperfusion injury. Hemoglobin 34:265–277.
   PubMed Web of Science ®Google Scholar
• Bamonti F, Fulgenzi A, Novembrino C, Ferrero ME. 2011. Metal chelation therapy in rheumathoid arthritis: A case report. Successful management of rheumathoid arthritis by metal chelation therapy. Biometals 24:1093–1098.
   PubMed Web of Science ®Google Scholar
• Baxter AJ, Krenzelok EP. 2008. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila) 46:1083–1084.
   PubMed Web of Science ®Google Scholar
• Blanusa M, Varnai VM, Piasek M, Kostial K. 2005. Chelators as antidotes of metal toxicity: Therapeutic and experimental aspects. Curr Med Chem 12:2771–2794.
   PubMed Web of Science ®Google Scholar
• Brown MJ, Willis T, Omalu B, Leiker R. 2006. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics 118:e534–e536.
   PubMed Web of Science ®Google Scholar
• Carven PC, Morrelli HF. 1975. Chelation therapy. West J Med 122:277–278.
   PubMedGoogle Scholar
• de Bie P, Muller P, Wijmenga C, Klomp LW. 2007. Molecular pathogenesis of Wilson and Menkes disease: Correlation of mutations with molecular defects and disease phenotypes. J Med Genet 44:673–688.
   PubMed Web of Science ®Google Scholar
• Discalzi G, Pira E, Herrero Hernandez E, Valentini C, Turbiglio M, Meliga F. 2000. Occupational Mn parkinsonism: Magnetic resonance imaging and clinical patterns following CaNa2-EDTA chelation. Neurotoxicology 21:863–866.
   PubMed Web of Science ®Google Scholar
• Elihu N, Anandasbapathy S, Frishman WH. 1998. Chelation therapy in cardiovascular disease: Ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane. J Clin Pharmacol 38:101–105.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. 2010. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148:466–475.
   PubMed Web of Science ®Google Scholar
• Foglieni C, Fulgenzi A, Ticozzi P, Pellegatta F, Sciorati C, Belloni D, Ferrero E, Ferrero ME. 2006. Protective effect of EDTA preadministration on renal ischemia. BMC Nephrol 7:5.
   PubMedGoogle Scholar
• Gil HW, Kang EJ, Lee KH, Yang JO, Lee EY, Hong SY. 2011. Effect of glutathione on the cadmium chelation of EDTA in a patient with cadmium intoxication. Hum Exp Toxicol 30:79–83.
   PubMed Web of Science ®Google Scholar
• Green DJ, O’Driscoll JG, Maiorana A, Scrimgeour NB, Weerasooriya R, Taylor RR. 1999. Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator function. Clin Exp Pharmacol Physiol 26:853–856.
   PubMed Web of Science ®Google Scholar
• Grier MT, Meyers DG. 1993. So much writing, so little science: A review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 27:1504–1509.
   PubMed Web of Science ®Google Scholar
• Haldane SL, Davis RM. 2009. Acute toxicity in five dogs after ingestion of a commercial snail and slug bait containing iron EDTA. Aust Vet J 87:284–286.
   PubMed Web of Science ®Google Scholar
• Hininger I, Waters R, Osman M, Garrel C, Fernholz K, Roussel AM, Anderson RA. 2005. Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy. Free Radic Biol Med 38:1565–1570.
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Kontoghiorghes GJ. 1992. Protocol for monitoring efficacy and toxicity in clinical trials with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Drugs Today (Barc.) 28:149–155.
   Google Scholar
• Kolnagou A, Kleanthous M, Kontoghiorghes GJ. 2010. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol 85:430–438.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Jackson MJ, Lunec J. 1986. In vitro screening of iron chelators using models of free radical damage. Free Radic Res Commun 2:115–124.
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Neocleous K, Kolnagou A. 2003. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 26:553–584.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. 2005. Regulatory molecules and chelators used for the control of essential and toxic metals in health and disease: From molecular interactions to clinical effects and applications. Curr Med Chem 12:2661–2662.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kolnagou A. 2005. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: The role of natural and synthetic chelators. Curr Med Chem 12:2695–2709.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. 2005. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr Med Chem 12:2663–2681.
   PubMed Web of Science ®Google Scholar
• Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. 2012. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J 163:7–12.
   PubMed Web of Science ®Google Scholar
• Lewin MR. 1997. Chelation therapy for cardiovascular disease. Review and commentary. Tex Heart Inst J 24:81–89.
   PubMed Web of Science ®Google Scholar
• Lin JL, Lin-Tan DT, Hsu KH, Yu CC. 2003. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 348:277–286.
   PubMed Web of Science ®Google Scholar
• Lin-Tan DT, Lin JL, Yen TH, Chen KH, Huang YL. 2007. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases. Nephrol Dial Transplant 22:2924–2931.
   PubMed Web of Science ®Google Scholar
• Morgan BW, Kori S, Thomas JD. 2002. Adverse effects in 5 patients receiving EDTA at an outpatient chelation clinic. Vet Hum Toxicol 44:274–276.
   PubMedGoogle Scholar
• Navas-Acien A, Silbergeld EK, Sharrett R, Calderon-Aranda E, Selvin E, Guallar E. 2005. Metals in urine and peripheral arterial disease. Environ Health Perspect 113:164–169.
   PubMed Web of Science ®Google Scholar
• Pippard MJ, Jackson MJ, Hoffman K, Petrou M, Modell CB. 1986. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 36:466–472.
   PubMedGoogle Scholar
• Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. 2007a. Novel treatment for diabetic nephropathy. J Am Soc Nephrol 18:329A.
   Google Scholar
• Rajapurkar MM, Gang S, Dabhi M, Kulkarni PS. 2007b. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol 18:57–58A.
   Google Scholar
• Roussel AM, Hininger-Favier I, Waters RS, Osman M, Fernholz K, Anderson RA. 2009. EDTA chelation therapy, without added vitamin C, decreases oxidative DNA damage and lipid peroxidation. Altern Med Rev 14:56–61.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. 2007. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115:1876–1884.
   PubMed Web of Science ®Google Scholar
• Tefler P, Goen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. 2006. Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica 91:1187–1192.
   PubMed Web of Science ®Google Scholar
• Owda AK, Alam MG, Shah SV. 2003. Environmental lead exposure and chronic renal disease. N Engl J Med 348:1810–2; author reply 1810.
   PubMedGoogle Scholar
• Villarruz MV, Dans A, Tan F. 2002. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev 4:CD002785.
   Google Scholar